Safety and efficacy of Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks children 6 – 11 years old with chronic hepatitis C infection
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2018
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 14 Aug 2018 Status changed from recruiting to completed as per the results.
- 02 Aug 2018 Results assessing the safety and efficacy (n=92, median age=9 years) published in the Hepatology.
- 07 Jul 2017 New trial record